[Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma]

No Shinkei Geka. 2000 Sep;28(9):789-94.
[Article in Japanese]


Six cases with recurrent or refractory primary central nervous system lymphoma were treated with a new chemotherapeutic regimen "DeVIC (dexamethasone, VP16, ifosfamide, carboplatin)". Five recurrent cases had a remission period for an average of 18 months after initial treatment, but relapse occurred. One refractory case had no response after initial treatment. Then these 6 cases were treated with 1-3 courses of DeVIC chemotherapy at intervals of 4 weeks. Two cases achieved complete remission, and 3 cases attained partial remission (response rate was 83%). One case showed no response after 1 course of DeVIC chemotherapy. However, in all cases re-relapse occurred 1-5 months after remission, and only 1 case is still alive. DeVIC chemotherapy produced a high response rate for recurrent central nervous system lymphoma, but re-relapse occurred after only a few months. The establishment of maintenance chemotherapy is required.

Publication types

  • Case Reports
  • Clinical Trial
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Neoplasms / drug therapy*
  • Carboplatin / administration & dosage
  • Combined Modality Therapy
  • Dexamethasone / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Humans
  • Ifosfamide / administration & dosage
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Remission Induction
  • Salvage Therapy
  • Treatment Outcome


  • Etoposide
  • Dexamethasone
  • Carboplatin
  • Ifosfamide

Supplementary concepts

  • ICE protocol 2